Akeso CEO says biliary tract cancer data could be a breakthrough
Akeso’s chief executive Michelle Xia told ChinaPharma that the company’s PD-1xVEGF bispecific antibody, ivonescimab, is generating strong interest after early biliary tract cancer results.
She noted that despite years of media attention, the recent data have put the program under an especially intense spotlight.
Xia emphasized that the trial outcomes suggest the drug may address an unmet need in a cancer type with limited treatment options, and she believes the findings could be a significant step forward for the company.
The discussion highlighted the potential impact on Akeso’s pipeline and future development plans, but no specific efficacy numbers or regulatory decisions were disclosed.
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Q&A: Akeso CEO spells out why she thinks its biliary tract cancer data are a big deal”
read at Endpoints ↗
comments(0)
5-min edit window · permanent after that